qPCR-HRM法检测NSCLC血清循环EGFR突变

摘要

Objective To investigate the possibility of detecting serum circulating EGFR mutations using qPCR-HRM method and compare the result with that of tumor tissue. Methods Serum circulating and tumor tissue EGFR mutation was detected by qPCR-HRM method in the 42 patients from PUMCH thoracic department from June, 2010 to July, 2011. Results EGFR mutation rate was 35.7% and 33.3% in blood and tissue, respectively. There is no significant difference in these 2 results (McNemar Test, P ＞ 0. 05 ). Κ is 0. 842 (P ＜ 0. 001). Conclusion The detection of EGFR mutation is highly consistent in serum and in tissue DNA samples by qPCR-HRM method.%目的 探讨利用qPCR-HRM法检测血清循环EGFR突变的可能性并与组织检测结果比较.方法 收集北京协和医院胸外科2010年6月至2011年7月收治的42例非小细胞肺癌(NSCLC)患者的石蜡标本及术前静脉血样,用qPCR-HRM法分别检测其EGFR突变情况.结果 42例血样中EGFR突变率35.7％ (15/42),肿瘤组织则为33.3％ (14/42).统计表明血浆和组织中的EGFR突变的检测结果未见差别(P＞0.05).k值为0.842 (P＜0.001).结论 使用qPCR-HRM法检测NSCLC患者血清与肿瘤组织的EGFR突变具有极好的一致性.